RenalTransplant near Bloomfield, NJ

Biography: Dr. Emond is the Vice Chairman of Surgery at Columbia University. He has over 30 years of experience performing liver transplantation and complex liver and biliary surgery in children and adults, including the first living donor liver transplantation (LDLT) in the United States. Dr. Emond has published extensively in this field and was the co-chair of the NIH A2ALL program for 13 years. In collaboration with the department of Medicine at Columbia, Dr. Emond recruited the leadership of the Columbia Center for Translational immunology that created the foundation for translational and clinical research in transplantation tolerance. This will lead the way to inducing transplant tolerance in liver patients with the mixed chimerism strategy. As Director of Transplantation at the Columbia University Medical Center Dr. Emond's activities foster clinical excellence and research across all 11 of the solid organ transplant programs at the Medical Center. In recognition of his national and international leadership in transplantation, Dr. Emond is the past president of the American Society of Transplant Surgeons, the pre-eminent association of a transplant surgery. Contribution to Science Living donor liver transplantation Dr. Emond has spent a substantial portion of his career developing living donor liver transplantation and studying the safety of the procedure in both the donor and recipient. He participated in the first living donor liver transplant in the United States and focused on refining the techniques of performing living donor liver transplants and split liver transplants. He was the national co-chair of the NIH-sponsored Adult-to-Adult Living Donor Liver Transplantation (A2ALL) consortium from 2002 to 2015 to study the safety and outcomes of living donor liver transplants. Hepatic resection/ischemia Dr. Emond developed techniques for surgical resection of liver tumors and studied the effect of ischemia during resection on postoperative liver function. These studies include the outcomes of the extent of hepatectomy, the biochemical response to major hepatectomy and ischemia-reperfusion injury of the liver in rodent models. He has studied the clinical safety of inducing total vascular exclusion to provide a bloodless field during the liver transection. This has applications in both liver cancer and living donor hepatectomies. Hepatocellular carcinoma treatment Dr. Emond has studied many aspects of managing patients with hepatocellular carcinoma. These studies have included characterizing the risk factors for recurrence of disease following transplantation due to comorbidities and tumor characteristics. The research team has also studied the optimal method of preventing tumor growth in patients with HCC on the liver transplant wait list in addition to optimal strategies of liver allocation to optimize outcomes following liver transplantation. These studies have contributed to proposed changes in UNOS exception point allocation for liver transplant candidates with HCC. Pediatric liver transplantation Dr. Emond helped develop the field of pediatric liver transplantation. Contributions to this field include: the use of living donors for pediatric patients; use of auxiliary liver transplants for metabolic diseases; use of partial liver grafts for pediatric patients; and technical modifications that improved outcomes for this patient population. Visit The Center for Liver Disease and Transplantation at columbiasurgery.org/liver

Care Philosophy: I strive to help patients treat the entire spectrum of their disease. We have direct contacts with multiple specialties to help patients get urgent appointments with other specialists if needed. We also have lists of support groups for those patients that need them

Biography: TO PROVIDE COMPASIONATE,CUTTING EDGE UROLOGIC CARE SUPPORTED BY EVIDENCE BASED MEDICINE THAT OPTIMIZES QUALITY OF LIFE FOR MY PATIENTS

Care Philosophy: Christopher S. Chandler, MD, values a patient-focused, multidisciplinary approach to achieve the optimal outcome for each patient. He uses leading technologies and techniques as he partners with a patient and their family to develop a treatment plan that meets their healthcare goals.

Biography: Joshua R. Sonett MD FACS is the Edward C. and Anne K. Weiskopf Professor of Surgical Oncology (in Surgery) at CUMC, Chief of General Thoracic Surgery and Director, The Price Family Center for Comprehensive Chest Care, Lung and Esophageal Center. He is instrumental in making the Thoracic Surgery section at Columbia University Medical Center one of the best in the U.S. and he is one of the youngest professors of surgery at a major academic institution in the United States. Dr. Sonett is best known for his work on the multidisciplinary treatment of lung and esophageal malignancies. Leading work in minimally invasive treatment of lung and esophageal cancer, Dr. Sonett and his team at Columbia are innovators in the development and teaching techniques of Video Assisted Thoracic Surgery (VATS) and Minimally Invasive Esophageal (MIE) surgery, allowing surgeons to incorporate these techniques into their daily practices. Dr. Sonett and his team make up one of the few programs in the country to employ a combination of maximal chemo and radiation and surgical therapies in the treatment of locally advanced lung malignancies. He is also a leader in multi-modality therapies for lung and esophageal cancers, and a pioneer in endo-bronchial palliation of benign and malignant airway stenosis. In the clinical area of lung transplantation, Dr. Sonett is best known for developing an extended-donor lung transplant criteria protocol. Extended donor criteria (EDC) applies to the use of organs that don't meet the usual criteria for transplantation due to various health problems, but are still healthy enough for a successful transplant (Liver MD 2006). Dr. Sonett and his team have been aggressively trying to alleviate the donor shortage by evaluating lungs that may be rejected from other centers (CS News 2005). Between 2001 and 2003, 53 percent of the lungs transplanted at NewYork-Presbyterian/Columbia were extended donor criteria lungs, with no difference in survival between EDC lung recipients and regular lung recipients. The Columbia programs has a 95% survival rate after one year and 83% after three years, which far surpasses the national average of 79% and 62% respectively (CS Lung News 2006). Dr. Sonett has been an invited speaker and principal and co- investigator of numerous clinical trials, author of numerous publications in renown journals such as the Journal of The American College of Cardiology, Annals of Thoracic Surgery, and the Journal of Heart and Lung Transplant, among many others. Dr. Sonett received his MD from Brody School of Medicine at East Carolina University Medical School, and completed his surgical residency at the University of Massachusetts, and Thoracic Fellowship at the University of Pittsburgh Medical Center. Professional Memberships include the New York Thoracic Society, The Society of Thoracic Surgeons, Fellow of the American College of Surgeons and member of the American Association for Thoracic Surgeons Dr. Sonett has received numerous award and honors including annual awards to America's Top Doctors, Castle Connolly America's Top Doctors for Cancer, New York Magazine's Best Doctors, the Barbara Neibauer Celebration of Life Award, Foundation for Thymic Cancer and the Humanitarian Award, Chesed of New Square.